Immugenia Inc. is a preclinical stage immuno-oncology company developing the next generation CAR therapy to treat and prevent relapses in hematological and solid tumors. This is achieved by engineering hematopoietic stem cells using proprietary specific promoters (SPICA) to express CAR in select immune cells leveraging the synergistic activity of T and NK cells. This provides patients with a one-and-done treatment to fight hard-to-treat cancers and prevent relapses.
Company Details
- Employees
- 3
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.immugenia.com
- Keywords
- Sherbrooke.
Immugenia Inc. Questions
Immugenia Inc.'s website is http://www.immugenia.com
Immugenia Inc.'s LinkedIn profile is https://www.linkedin.com/company/immugenia-inc
Immugenia Inc. has
3 employees.
View email and phone details for 3
employees at Immugenia Inc..
Immugenia Inc.'s industry is
Biotechnology Research
Immugenia Inc.'s top competitors are
Tatum Bioscience,
Neuroservo,
Epitopea,
Ovensa Inc.,
Pytri,
Morphocell Technologies,
Seragene Therapeutics,
Cqdm,
9bio Therapeutics,
Biomimir.
Immugenia Inc.'s categories are Biotechnology Research
